We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA STUDIES DRUG REVIEW FAILURES; PGx GUIDANCE ON HOLD
FDA STUDIES DRUG REVIEW FAILURES; PGx GUIDANCE ON HOLD
June 9, 2004
The FDA has signed a contract with an independent consultant to examine why first-cycle drug reviews fail, the head of the Center for Drug Evaluation and Research (CDER) said late Tuesday at the Biotechnology Industry Organization’s annual convention in San Francisco.